State Street Holds 4% Of Cullinan As Drug Developer Advances Its Lupus Program

The passive position was dated September 30; Cullinan reported preliminary velinotamig results Sunday.

Share
State Street Holds 4% Of Cullinan As Drug Developer Advances Its Lupus Program

State Street reported a 4% passive stake in Cullinan Therapeutics, which develops drugs for autoimmune diseases and cancer, in an SEC ownership filing Tuesday. The position comprises 2,604,105 common shares and is dated September 30, 2026—before Cullinan's preliminary lupus-treatment update Sunday.

A Passive Position, Not Control

State Street certified that the shares were bought and are held as part of its regular business, rather than for an effort to alter or influence Cullinan's control. The 4% figure measures its beneficial ownership of the common-stock class.

State Street reported shared voting authority over 2,476,651 shares and shared authority to dispose of 2,604,105 shares. The ownership date separates the holding from Sunday's clinical announcement: Tuesday was the filing date, not the date attached to the position.

Cullinan's market value was $755 million as of Tuesday at 7:09 a.m. ET.

Early Lupus Results And A Broader Pipeline

Cullinan reported Sunday that eight of nine evaluable patients receiving experimental velinotamig improved at least four points on a measure of lupus activity. The patients had lupus that continued despite standard treatment.

Four patients achieved complete kidney responses within 24 weeks, with urine protein below 500 milligrams over 24 hours. Cullinan Chief Medical Officer Jeffrey Jones said the preliminary findings supported its global development plan for velinotamig.

Cullinan focuses on T cell engagers—drugs that guide the body's T cells toward target cells. It licensed velinotamig from Chongqing Genrix Biopharmaceutical for autoimmune diseases outside Greater China.

Its pipeline also includes early-stage CLN-978 trials in lupus, rheumatoid arthritis and Sjögren's disease, and an early-stage CLN-049 trial in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

Cullinan also works with a Taiho Pharmaceutical affiliate on the oral lung-cancer drug zipalertinib, which Taiho will commercialize. Cullinan is eligible for milestone payments and 50% of potential future US pre-tax sales profits.

Cullinan CEO Nadim Ahmed and Jones are scheduled to participate in the UBS Global Biopharma Conference in London on November 17.

Sources

More on Cullinan Therapeutics

All Cullinan Therapeutics (CGEM) coverage →